A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

Overview

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck.

Ferumoxytol imaging will also be investigated at US sites as an exploratory endpoint.

Full Title of Study: “A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2016

Interventions

  • Drug: BIND-014 (docetaxel nanoparticles for injectable suspension)
    • docetaxel nanoparticles for injectable suspension

Clinical Trial Outcome Measures

Primary Measures

  • To determine the objective response rate (ORR) in patients with advanced urothelial carcinoma (transitional cell carcinoma), cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck.
    • Time Frame: 18 weeks
    • Patients will be followed for ORR for an expected average of 18 weeks

Secondary Measures

  • Progression Free Survival
    • Time Frame: Change in tumor size will be assessed using RECIST measurements. RECIST assessments will be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average of 18 weeks.
  • Overall Survival
    • Time Frame: Participants will be followed for survival, an expected average 24 weeks after treatment discontinuation
  • Best Response
    • Time Frame: Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks
  • Duration of Response
    • Time Frame: Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks
  • Time to Response
    • Time Frame: change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 relative to first dose of study drug
  • Disease Control Rate
    • Time Frame: Change in tumor size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks
  • Safety and Tolerability, as measured by number of participants with adverse events
    • Time Frame: Measured from first dose of study drug until 30 days after study discontinuation

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosis of advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree or squamous cell carcinoma of the head and neck.

2. Progressive disease after ≥ 1 prior chemotherapy regimen.

3. Patients with brain metastases are eligible if asymptomatic and neurologically stable for at least 4 weeks and are not taking any medications contraindicated

4. Chemotherapy must have been completed at least 4 weeks prior to initiation of study medication

5. ECOG performance status 0-1

6. Tumors must have measurable disease as per RECIST (version 1.1);

7. Female or male, 18 years of age or older

8. Adequate organ function

9. Life expectancy of > 3 months

Exclusion Criteria

1. Current treatment on another therapeutic clinical trial

2. Prior treatment with docetaxel within 6 months of enrollment

3. Stage II, III or IV cardiac failure

4. Carcinomatous meningitis

5. Ongoing cardiac dysrhythmias

6. Peripheral neuropathy

7. Serious concomitant conditions

8. Pregnant or breast feeding

9. Known sensitivity to ferumoxytol

10. Hypersensitivity to polysorbate 80

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • BIND Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.